

Charles H. Chevalier
GIBBONS P.C.
One Gateway Center
Newark, New Jersey 07102-5310
(973) 596-4611
cchevailier@gibbonslaw.com

Christine A. Gaddis
GIBBONS P.C.
141 West Front Street, Suite 240
Red Bank, New Jersey 07701
(732) 704-5801
cgaddis@gibbonslaw.com

*Attorneys for Plaintiff
American Regent, Inc.*

OF COUNSEL:

Dennies Varughese, Pharm. D.
Uma Everett (*pro hac vice* to be filed)
Adam LaRock (*pro hac vice* to be filed)
Alex Alfano (*pro hac vice* to be filed)
Ryan Conkin (*pro hac vice* to be filed)
Sterne, Kessler, Goldstein & Fox
P.L.L.C.
1101 K Street, NW, 10th Floor
Washington, DC 20005
(202) 371-2600
dvarughese@sternekessler.com
ueverett@sternekessler.com
alarock@sternekessler.com
aalfano@sternekessler.com
rconkin@sternekessler.com

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

AMERICAN REGENT, INC.,

Plaintiff,

v.

SUN PHARMACEUTICAL INDUSTRIES
LIMITED and SUN PHARMACEUTICAL
INDUSTRIES, INC.

Defendants.

Civil Action No. 24-cv-11126

(Filed Electronically)

COMPLAINT FOR PATENT INFRINGEMENT TO SUN

Plaintiff American Regent, Inc. (“ARI” or “Plaintiff”), by its undersigned attorneys, for its Complaint against Defendants Sun Pharmaceutical Industries Limited and Sun Pharmaceutical Industries, Inc. (collectively, “Sun” or “Defendant”) alleges as follows:

NATURE OF THIS ACTION

1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C. § 100 *et. seq.*, arising from Sun’s submission to the United States Food and Drug Administration (“FDA”) of Abbreviated New Drug Application No. 219547 (“the ANDA”) which contains a certification of the type described in Section 505(j)(2)(A)(vii)(IV) of the Federal Food, Drug, and Cosmetic Act (“Paragraph IV Certification”) seeking approval to engage in the commercial manufacture, use, sale, and/or importation of a generic version of ARI’s Selenious Acid products (“the ANDA Product”) prior to the expiration of United States Patent No. 12,150,957 (“the ’957 patent” or the “Asserted Patent”). As discussed below, this case involves the same ANDA No. 219547 and thus is a related case to *American Regent, Inc. v. Sun Pharmaceutical Industries Limited, et al*, C.A. No. 24-7810 (D.N.J.) (the “Related Action”).

THE PARTIES

2. ARI is a corporation organized and existing under the laws of the State of New York, with a principal place of business at 5 Ramsey Road, Shirley, New York 11967.

3. On information and belief, Sun Pharmaceutical Industries Limited is a corporation organized and existing under the laws of India with its principal place of business at Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India.

4. On information and belief, Sun Pharmaceutical Industries, Inc. is a corporation organized and existing under the laws of the State of Delaware with a principal place of business at 2 Independence Way, Princeton, New Jersey 08450.

JURISDICTION AND VENUE

5. This is a civil action for patent infringement arising under the patent laws of the United States, 35 U.S.C. § 100 *et. seq.*, and jurisdiction is proper under 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202.

6. On information and belief, this Court has personal jurisdiction over Sun Pharmaceutical Industries Limited, under the New Jersey state long arm statute and consistent with due process of law because Sun has extensive contacts with the State of New Jersey and regularly does business in this judicial district. Further, Sun plans to sell its ANDA Product in the State of New Jersey, which provides an independent basis for personal jurisdiction here.

7. On information and belief, this Court has personal jurisdiction over Sun Pharmaceutical Industries, Inc., under the New Jersey state long arm statute and consistent with due process of law, because Sun Pharmaceutical Industries, Inc. maintains its principal place of business in New Jersey.

8. This Court has personal jurisdiction over Sun Pharmaceutical Industries Limited because it has purposefully availed itself of the rights and benefits of New Jersey law by engaging in systematic and continuous contact with the State of New Jersey. On information and belief, Sun Pharmaceutical Industries Limited regularly and continuously transacts business within New Jersey, including by making pharmaceutical products for sale in New Jersey and selling pharmaceutical products in New Jersey. On information and belief, Sun Pharmaceutical Industries Limited derives substantial revenue from the sale of those products in New Jersey and has availed itself of the privilege of conducting business within New Jersey.

9. This Court has personal jurisdiction over Sun Pharmaceutical Industries, Inc. by virtue of, inter alia, its systematic and continuous contacts with the State of New Jersey. On information and belief, Sun Pharmaceutical Industries, Inc.'s principal place of business is in Princeton, New Jersey. On information and belief, Sun Pharmaceutical Industries, Inc. purposefully has conducted and continues to conduct business in this judicial district. By virtue of

its physical presence in New Jersey, this Court has personal jurisdiction over Sun Pharmaceutical Industries, Inc.

10. On information and belief, Sun Pharmaceutical Industries, Inc. and Sun Pharmaceutical Industries Limited work in concert with respect to the regulatory approval, manufacturing, marketing, sale, and distribution of generic pharmaceutical products throughout the United States, including in this judicial district.

11. On information and belief, Sun Pharmaceutical Industries, Inc. is the United States agent acting at the direction of, and for the benefit of, Sun Pharmaceutical Industries Limited regarding the ANDA.

12. This Court has personal jurisdiction over Sun because Sun has purposefully availed itself of the rights and benefits of New Jersey law by engaging in systematic and continuous contact with the State of New Jersey. On information and belief, Sun Pharmaceutical Industries, Inc. is registered with the State of New Jersey's Division of Revenue and Enterprise Services as a business operating in New Jersey under Business Id. No. 0101055400, and Sun Pharmaceutical Industries, Inc. is also licensed to do business with the New Jersey Department of Health as a "Manufacturer and Wholesale[r]" of pharmaceuticals in the State of New Jersey under Registration Number 5003358. On information and belief, Sun regularly and continuously transacts business within New Jersey, including by making pharmaceutical products for sale in New Jersey and selling pharmaceutical products in New Jersey. On information and belief, Sun derives substantial revenue from the sale of those products in New Jersey and has availed itself of the privilege of conducting business within New Jersey.

13. This Court has personal jurisdiction over Sun because, on information and belief, Sun derives substantial revenue from directly or indirectly selling generic pharmaceutical products

and/or pharmaceutical ingredient(s) used in generic pharmaceutical products sold throughout the United States, including in this judicial district.

14. This Court has personal jurisdiction over Sun Pharmaceutical Industries Limited because it has previously availed itself of the legal protections of the State of New Jersey by, among other things, not contesting personal jurisdiction and through the assertion of counterclaims in suits brought in New Jersey, including in at least *Dexcel Pharma Technologies Ltd. et al. v. Sun Pharma Global FZE et al.*, No. 15-08017, ECF No. 18 (D.N.J. Feb. 5, 2016).

15. This Court has personal jurisdiction over Sun Pharmaceutical Industries, Inc. because it has previously availed itself of the legal protections of the State of New Jersey by, among other things, not contesting personal jurisdiction and through the assertion of counterclaims in suits brought in New Jersey, including in at least *Astellas Pharma Inc. v. Sun Pharm. Industries, Inc.*, C.A. No. 22-7357 (D.N.J.) and *Orexo AB v. Sun Pharm. Industries Ltd.*, C.A. No. 21-17941 (D.N.J.).

16. This Court has personal jurisdiction over Sun because, *inter alia*, Sun has committed an act of patent infringement under 35 U.S.C. § 271(e)(2) and intends a future course of conduct that includes acts of patent infringement in New Jersey. These acts have led and will lead to foreseeable harm and injury to ARI in New Jersey. Further, on information and belief, following approval of the ANDA, Sun will make, use, import, sell, and/or offer for sale the ANDA Products in the United States, including in New Jersey, prior to the expiration of the Asserted Patent.

17. In the alternative, this Court has personal jurisdiction over Sun Pharmaceutical Industries Limited because the requirements of Federal Rule of Civil Procedure 4(k)(2)(A) are met as (a) ARI's claims arise under federal law; (b) Sun Pharmaceutical Industries Limited is a foreign

defendant not subject to general personal jurisdiction in the courts of any state; and (c) Sun Pharmaceutical Industries Limited has sufficient contacts with the United States as a whole, including, but not limited to, preparing and submitting an ANDA to the FDA and/or manufacturing and/or selling pharmaceutical products distributed throughout the United States, such that this Court's exercise of jurisdiction over Sun Pharmaceutical Industries Limited satisfies due process.

18. Venue is further proper in this Court under 28 U.S.C. §§ 1391 and/or 1400(b).

19. On information and belief, venue is proper in this judicial district under 28 U.S.C. §§ 1391 and 1400(b) at least because Sun Pharmaceutical Industries, Inc. has committed acts of infringement in New Jersey and has a regular and established place of business in New Jersey. Sun Pharmaceutical Industries Limited is a foreign company not residing in any United States judicial district and may be sued in any judicial district. 28 U.S.C. § 1391(c)(3).

20. On information and belief, Sun has committed acts of infringement under the meaning of 28 U.S.C. § 1400(b) by submitting the ANDA to the FDA, by taking steps indicating its intent to market the ANDA Products in New Jersey, and by the acts that it non-speculatively intends to take in New Jersey if the ANDA receives final FDA approval.

21. On information and belief, Sun Pharmaceutical Industries, Inc. has a regular and established place of business in New Jersey under the meaning of 28 U.S.C. § 1400(b) because, *inter alia*, its principal place of business is in New Jersey. As set forth above, on information and belief, Sun Pharmaceutical Industries, Inc. maintains regular and established places of business in New Jersey, including its headquarters, offices, laboratories, and/or facilities at 2 Independence Way, Princeton, New Jersey 08450.

22. On information and belief, Sun Pharmaceutical Industries Limited and Sun Pharmaceutical Industries, Inc. have taken steps in New Jersey, including preparing the ANDA

and communicating with the FDA regarding the ANDA, that indicate their intent to market the ANDA Products. As set forth above, on information and belief, if the ANDA is approved, Sun intends to commit acts of patent infringement in New Jersey, including marketing, distributing, offering for sale, and/or selling the ANDA Products.

BACKGROUND

23. ARI holds New Drug Application (“NDA”) No. 209379 for Selenious Acid ((1) eq. 600 mcg Selenium/10 mL (eq. 60 mcg Selenium/mL), (2) eq. 60 mcg Selenium/mL (eq. 60 mcg Selenium/mL), and (3) eq. 12 mcg Selenium/2 mL (eq. 6 mcg Selenium/mL)), which was originally approved by the FDA on April 30, 2019, which ARI manufactures and sells in this judicial district and throughout the United States.

24. The use of ARI’s Selenious Acid products is covered by one or more claims of the Asserted Patent.

25. ARI is the owner of the ’957 patent, entitled “Trace element compositions, methods of making and use,” which was duly and legally issued on November 26, 2024. A copy of the ’957 patent is attached as Exhibit A.

26. The ’957 patent has been listed in connection with ARI’s Selenious Acid products in the FDA’s publication Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”).

27. As indicated in the Orange Book, the patent expiration date for the ’957 patent is July 1, 2041.

28. On information and belief, Sun was responsible for preparing the ANDA which contained a Paragraph IV Certification.

29. By letter dated June 11, 2024 (“the Notice Letter”), Sun notified ARI that, pursuant to the Federal Food, Drug, and Cosmetic Act, Sun had submitted the ANDA with a Paragraph IV

Certification to the FDA to seek approval to engage in the commercial manufacture, use, offer for sale, sale, and/or importation of the ANDA Product prior to the expiration of U.S. Patent No. 11,998,565 (“the ’565 patent”), which is at issue in the Related Action.

30. On information and belief, Sun submitted the ANDA to the FDA, which contained a Paragraph IV Certification asserting that the ’565 patent will not be infringed by the manufacture, use, offer for sale, sale, or importation of the ANDA Product, or alternatively, that the ’565 patent is invalid.

31. Since ARI received the Notice Letter and filed its complaint against Sun in the Related Action, the ’957 patent has been listed in connection with ARI’s Selenious Acid products in the Orange Book.

32. On information and belief, the ANDA Product is a generic version of ARI’s Selenious Acid products ((1) eq. 600 mcg Selenium/10 mL (eq. 60 mcg Selenium/mL) as its reference listed drug, containing the same or equivalent ingredients in the same or equivalent amounts.

33. In the Notice Letter, Sun disclosed that the ANDA Product is: Selenious Acid Injection, USP, 600 mcg/10 mL (60 mcg/mL) of selenium in a 10 mL pharmacy bulk package.

34. On information and belief, the ANDA Product contains the same or equivalent ingredients in the same or equivalent amounts as ARI’s Selenious Acid products ((1) eq. 600 mcg Selenium/10 mL (eq. 60 mcg Selenium/mL)).

35. On information and belief, the ANDA Product will feature the same or equivalent chemical and therapeutic properties as ARI’s Selenious Acid products.

COUNT I: INFRINGEMENT OF THE ’957 PATENT

36. ARI realleges paragraphs 1–35 as if fully set forth herein.

37. Sun's submission of the ANDA with a Paragraph IV Certification to obtain approval to engage in the commercial manufacture, use, offer for sale, sale and/or importation of the ANDA Product in or into the United States, prior to the expiration of the '957 patent, constitutes direct and indirect infringement of the '957 patent pursuant to 35 U.S.C. § 271(e)(2)(A), either literally or under the doctrine of equivalents.

38. On information and belief, the ANDA Product, if approved by the FDA, will be manufactured, used, offered for sale, sold, and/or imported in or into the United States by Sun or on its behalf, and will be administered by patients and/or medical practitioners in the United States according to the directions and instructions in the proposed package insert, which will constitute direct infringement by patients and/or medical practitioners of one or more claims of the '957 patent, under 35 U.S.C. § 271(a), either literally or under the doctrine of equivalents. On information and belief, the administration of the ANDA Product will occur with Sun's specific intent and encouragement, and will constitute conduct that Sun knows or should know will occur. On information and belief, Sun will actively induce, encourage, aid, and abet that conduct by patients and/or medical practitioners, with knowledge and specific intent that the conduct will be in contravention of ARI's rights under the '957 patent.

39. On information and belief, Sun's manufacture, use, offer for sale, sale, and/or importation of the ANDA Product, once the ANDA with a Paragraph IV Certification is approved by the FDA, would constitute direct infringement under 35 U.S.C. § 271(a), induced infringement under 35 U.S.C. § 271(b), and/or contributory infringement under 35 U.S.C. § 271(c) of one or more claims of the '957 patent, either literally or under the doctrine of equivalents. On information and belief, Sun intends that the ANDA Product be used by patients and medical professionals. Also, on information and belief, Sun knows that the ANDA Product is especially made or adapted

for use in infringing the '957 patent, and that the ANDA Product is not suitable for substantial non-infringing use.

40. ARI will be irreparably harmed if Sun is permitted to make, use, sell, offer to sell, and/or import the ANDA Product in or into the United States, and is not enjoined from doing so. ARI is entitled to relief provided by 35 U.S.C. §§ 271(e)(4) and/or 283, including an order of this Court that the effective date of approval of the ANDA be a date that is not earlier than the expiration date of the '957 patent, or any later expiration of exclusivity for the '957 patent to which ARI is or becomes entitled, and an injunction against such infringement. ARI does not have an adequate remedy at law.

41. Sun has had knowledge of the '957 patent since at least October 11, 2024, when ARI emailed all defendants in the Related Action to inform them that the '957 patent would issue in due course.

42. This case is “exceptional,” and ARI is entitled to an award of reasonable attorneys’ fees under 35 U.S.C. § 285.

PRAYER FOR RELIEF

WHEREFORE, ARI prays that this Court grant the following relief:

(a) A judgment under 35 U.S.C. § 271(e)(2)(A) that Sun has infringed at least one claim of the Asserted Patent through Sun’s submission of the ANDA with a Paragraph IV Certification to the FDA seeking approval to commercially manufacture, use, offer for sale, sell, and/or import within or into the United States the ANDA Product before the expiration of the Asserted Patent;

(b) A judgment under 35 U.S.C. §§ 271(a), (b), and/or (c) that Sun’s commercial manufacture, use, offer for sale, sale, and/or importation within or into the United States of the ANDA Product before the expiration of the Asserted Patent will infringe, actively

induce infringement, and/or contribute to the infringement of at least one claim of the Asserted Patent;

(c) An order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective date of any FDA approval of the ANDA, shall not be earlier than the latest expiration date of the Asserted Patent, including any extensions and/or additional periods of exclusivity to which ARI is or becomes entitled;

(d) The entry of a permanent and/or preliminary injunction enjoining Sun, and its affiliates and subsidiaries, and each of their officers, agents, servants, and employees, from making, having made, using, offering to sell, selling, marketing, distributing, and importing in or into the United States the ANDA Product, or any product that infringes the Asserted Patent, or inducing or contributing to the infringement of the Asserted Patent until after the expiration date of the Asserted Patent, including any extension and/or additional periods of exclusivity to which ARI is or becomes entitled, in accordance with 35 U.S.C. §§ 271(e)(4)(B) and 283;

(e) The entry of a permanent and/or preliminary injunction enjoining Sun, and its affiliates and subsidiaries, and each of their officers, agents, servants, and employees, from seeking, obtaining, or maintaining approval of the ANDA until the expiration of the Asserted Patent, in accordance with 35 U.S.C. §§ 271(e)(4)(B) and 283;

(f) Damages or other monetary relief to ARI if Sun engages in commercial manufacture, use, offers to sell, sale, and/or importation in or into the United States of the ANDA Product prior to the expiration of the Asserted Patent, including any extensions and/or additional periods of exclusivity to which ARI is or becomes entitled;

(g) A finding that this is an exceptional case pursuant to 35 U.S.C. § 285 and awarding ARI its attorneys' fees incurred in this action; and

(h) Such further relief as this Court deems proper and just.

JURY DEMAND

Pursuant to Federal Rule of Civil Procedure 38(b), Plaintiffs hereby demand a trial by jury on all issues triable to a jury. Specifically, Plaintiffs demand a jury trial in the event that there is a launch at risk and damages are in issue.

Dated: December 13, 2024

By: s/ Charles H. Chevalier
Charles H. Chevalier
GIBBONS P.C.
One Gateway Center
Newark, New Jersey 07102-5310
(973) 596-4611
cchevailier@gibbonslaw.com

Christine A. Gaddis
GIBBONS P.C.
141 West Front Street, Suite 240
Red Bank, New Jersey 07701
(732) 704-5801
cgaddis@gibbonslaw.com

OF COUNSEL:

Dennies Varughese, Pharm. D.
Uma Everett
Adam LaRock
Alex Alfano
Ryan Conkin
Sterne, Kessler, Goldstein & Fox P.L.L.C.
1101 K Street, NW, 10th Floor
Washington, DC 20005
(202) 371-2600
dvarughese@sternekessler.com
ueverett@sternekessler.com
alarock@sternekessler.com
aalfano@sternekessler.com
rconkin@sternekessler.com

*Attorneys for Plaintiff
American Regent, Inc.*